Genmab — December 2016
-
Ja klart
og selv AB er ved at finde ud af at de "ror den forkerte vej" 
-
2 advokatfirmaer undersøger Sgens' 15% fald i tirsdags http://www.marketwatch.com/story/shareholder-alert-bronstein-gewirtz-grossman-llc-announces-investigation-of-seattle-genetics-inc-sgen-2016-12-28 http://www.businesswire.com/news/home/20161228005333/en/
-
Ofatumumab Versus Rituximab ORCHARRD http://ascopubs.org/doi/pdf/10.1200/JCO.2016.69.0198
-
"In conclusion, results of this study showed that use of ofatumumab instead of rituximab in conjunction with standard
salvage chemotherapy was not able to overcome treatment resistance in early relapsed or refractory DLBCL. Clearly, for these patients, other treatment approaches are eagerly awaited."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind